任命中国总裁，仪器巨头重磅官宣“三连发”

Core Viewpoint - Merck has recently made significant announcements, including the appointment of a new CEO and the acquisition of JSR Life Sciences' chromatography business, aimed at enhancing its biopharmaceutical production capabilities [4]. Group 1: Leadership Changes - Merck officially announced the appointment of Kai Beckmann as the new CEO, effective May 1, 2026 [4]. - Rogier Janssens will take over as the President of Merck China starting February 1, 2026, and will also lead Merck Life Science in China from January 1, 2026, to improve market responsiveness [5][10]. - Current President of Merck China, Marc Horn, will return to Germany for family reasons after contributing significantly to the company's operations and reputation in China over the past two years [6][13]. Group 2: Strategic Acquisitions - Merck announced the acquisition of JSR Life Sciences' chromatography business on October 15, 2023, which is expected to enhance its downstream product offerings and support more efficient biopharmaceutical production [4]. Group 3: Commitment to China - Merck has invested nearly 7 billion RMB in China over the past decade, establishing a strong local presence with approximately 4,500 employees and 21 legal entities [13]. - The company aims to continue deepening its engagement in China, aligning its three main business areas—Life Science, Healthcare, and Electronics—with national strategies to drive sustainable growth and innovation [8][13].